유성용 (Cedars-Sinai Medical Center)님 | 한빛사연구자 > 한빛사

Cedars-Sinai Medical Center

CV File

최종업데이트 2026.01.15.

Computational frameworks for enhanced extracellular vesicle biomarker discovery
- Exp. Mol. Med., 14 January 2026 | https://doi.org/10.1038/s12276-025-01622-x
- 2026-01
- 바이오·의료융합
- 한빛사논문
Redirecting microglia phenotype via inhibition of NFAT1 ameliorates deficits in mouse model of synucleinopathies
- Exp. Mol. Med., 17 November 2025 | https://doi.org/10.1038/s12276-025-01564-4
- 2025-11
- 바이오·의료융합
- 한빛사논문
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients
- J. Exp. Clin. Cancer Res., Published: 01 May 2025 | https://doi.org/10.1186/s13046-025-03379-7
- 2025-05
- 바이오·의료융합
- 한빛사논문
Metastatic Tumor Growth in Steatotic Liver is Promoted by HAS2-Mediated Fibrotic Tumor Microenvironment
- J. Clin. Invest., Feb 13 2025, e180802 | https://doi.org/10.1172/JCI180802
- 2025-02
- 생명과학
- 한빛사논문
- 유성용(Cedars-Sinai Medical Center)
B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer
- Drug Resist. Update, Jan 28 2025, 79 S1368-7646(25)00007-X | https://doi.org/10.1016/j.drup.2025.101207
- 2025-01
- 바이오·의료융합
- 한빛사논문
- 유성용(Cedars-Sinai Medical Center)
Prostate cancer extracellular vesicle digital scoring assay – a rapid noninvasive approach for quantification of disease-relevant mRNAs
- Nano Today, 2023 Feb:48:101746 | https://doi.org/10.1016/j.nantod.2022.101746
- 2023-02
- 바이오·의료융합
- 한빛사논문
Prostate cancers with distinct transcriptional programs in Black and White men
- Genome Med., Jul 23 2024, 16 (1) | https://doi.org/10.1186/s13073-024-01361-0
- 2024-07
- 생명과학
- 한빛사논문
- 유성용(Cedars-Sinai Medical Center)
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer
- Nucleic Acids Res., Jun 27 2024, gkae547 | https://doi.org/10.1093/nar/gkae547
- 2024-06
- 생명과학
- 한빛사논문
- 유성용(Cedars-Sinai Medical Center)
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti–PD-L1 Immune Checkpoint Therapy
- JNCI-J. Natl. Cancer Inst., Volume 114, Issue 10, October 2022, Pages 1380–1391 | https://doi.org/10.1093/jnci/djac140
- 2022-10
- 생명과학
- 한빛사논문
- 유성용(Cedars-Sinai Medical Center)
  Interview 2
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
- Nat. Med., Published: 26 November 2018 | https://doi.org/10.1038/s41591-018-0241-1
- 2018-11
- 생명과학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기